CoRIS Cohort
Our
Only by working together can we advance our understanding of HIV.
International
COLLABORATIONS
CoRIS works together with all HIV-related entities. Our scientific structure contributes to advancing our understanding of HIV.
HIV SURVEILLANCE AND
RISK BEHAVIOUR UNIT
CoRIS works closely and regularly with the HIV Surveillance and Risk Behaviour Unit of the National Epidemiology Centre, coordinated by Asunción Díaz. CoRIS data have contributed to estimating the HIV Care Continuum in Spain. This estimate, which is made by the HIV Surveillance Unit, allows us to know where our country stands as opposed to the 95-95-95 targets set by UNAIDS for 2030. This is an ambitious goal, which aims to achieve that by 2030: 95% of HIV-infected people are diagnosed; 95% of diagnosed people are on antiretroviral treatment; 95% of people on treatment have suppressed viral loads. On a different note, CoRIS data have also contributed to estimating recent infections among newly diagnosed HIV cases in our country.
The cooperation between CoRIS and the HIV Surveillance and Risk Behaviour Unit allows us to align research and public health goals, so that our joint work addresses the needs of people living with HIV (PLWH).
You can find more information about this collaboration on https://www.isciii.es/QueHacemos/Investigacion/EpidemiologiaSaludPublica/Paginas/Detalle.aspx?ItemId=8
SPANISH AIDS NATIONAL PLAN
On a regular basis, we work together with the Spanish AIDS National Plan by supplying CoRIS data that can contribute to addressing public health issues raised by HIV. Furthermore, in the context of the COVID-19 pandemic, CoRIS Coordination Unit is working jointly with the Spanish AIDS National Plan and HIV Surveillance and Risk Behaviour Unit on the project “Incidence and severity of COVID-19 among HIV-positive people on ART in Spain”. The goal of this project is to estimate the incidence, clinical severity and mortality due to COVID-19 among HIV-infected individuals on ART, based on their nucleoside/nucleotide analogues and third drug schedule.
You can find more information about this collaboration on https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/home.htm
SEISIDA
We often collaborate with the Spanish Interdisciplinary Society for the Study of AIDS (SEISIDA). One of our common interests is the health-related quality of life of PLWH, which is why we work on a project on this topic together with them and the Barcelona Institute for Global Health.
You can find more information about this collaboration on https://www.seisida.net/
CESIDA
Collaborating with the civil society is essential for CoRIS. For that reason, we work with the State Coordinator for HIV and AIDS (CESIDA) on a regular basis. For example, we ask them to help us spread our research findings, so the knowledge acquired can reach PLWH.
You can find more information about this collaboration on https://cesida.org/
GeSIDA
CoRIS also works together with GeSIDA, the SEIMC AIDS Study Group. This entity comprises healthcare professionals whose goals are to promote and spread research and education in the field of HIV infection, in order to provide quality assistance for patients.
GeSIDA National Congress, which takes place on a yearly basis, hosts the Academic Meeting of the Spanish AIDS Research Network. This is a unique platform to spread the research work conducted within the CoRIS cohort.
You can find more information about this collaboration on https://gesida-seimc.org/
International
collaborations
CoRIS participates in the main HIV cohort international collaborations, because we believe scientific advances should have no borders. CoRIS contributes by sharing CoRIS data with different collaborations, as well as leading research projects within their framework.
ART-CC
The ART-CC international collaboration (Antiretroviral Therapy Cohort Collaboration), led by Jonathan Sterne from the University of Bristol, comprises 20 HIV cohort studies from Europe and North America.
Initially, the collaboration was established to study the prognosis of PLWH after starting antiretroviral treatment. In fact, the assessment of the prognosis of HIV patients during the first 5 years undergoing antiretroviral treatment (ART) is one of its greatest accomplishments.
Within the framework of this collaboration, CoRIS Coordination Unit has led different projects to study gender and racial/ethnic health disparities among HIV-positive people on ART.
The ART-CC collaboration currently focuses its scientific research on assessing the impact on alcohol intake and substance abuse on the prognosis of PLWH. It also concentrates on describing the frequency of hospital admission and its causes, as well as global mortality and its causes among HIV-positive people after starting ART.
You can find more information about this collaboration on http://www.bristol.ac.uk/art-cc/
HIV-CAUSAL
The HIV-CAUSAL collaboration, led by Miguel Hernán from Harvard School of Public Health, is a multinational consortium comprising HIV cohort studies from 6 European countries, Brazil, Canada, and the United States. The research team is made up of researchers from each participating cohort, among which is CoRIS, and from the coordinating centre.
The HIV-CAUSAL collaboration was created to tackle challenging methodological issues arising when comparative effectiveness and safety research is conducted in HIV cohort studies. For more than a decade, the HIV-CAUSAL collaboration has been at the forefront of the development and implementation of statistical methods to compare the effectiveness of clinical strategies of HIV cohorts. Some of the methods initiated by this collaboration have achieved a breakthrough in HIV cohort analysis in the 21st century. Along these lines, the collaboration makes it possible for leading HIV observational research groups to receive training on these methods. Several CoRIS researchers have enjoyed the privilege of participating in training stages at Harvard School of Public Health.
HIV-CAUSAL findings have played a crucial role in the debate, to a great extent solved, about the optimal time for ART initiation. The collaboration’s recent research has improved understanding of the impact of ART on opportunistic infections, neurological disorders and drug resistance. It has also contributed to studying dynamic treatment and monitoring strategies for PLWH.
You can find more information about this collaboration on https://www.hsph.harvard.edu/causal/hiv/
CASCADE
The CASCADE Collaboration (Concerted Action on SeroConversion to AIDS and Death in Europe), led by Kholoud Porter from the University College of London, comprises 29 cohorts of PLWH in Europe, Canada, Australia and Sub-Saharan Africa with known dates of HIV seroconversion (seroconverters).
HIV-positive people who are part of CASCADE were diagnosed with HIV at an early stage, and are thus more likely to start antiretroviral treatment. These seroconverters represent the best scenario in terms of what can be achieved through HIV early onset and diagnosis.
CASCADE’s main objective is to monitor the entire course of HIV infection in newly infected individuals. In fact, since its creation in 1997, the collaboration has provided key data on the course of HIV infection from the time of infection onwards. Within the framework of this collaboration, CoRIS has led several projects aimed at studying gender and race/geographical origin disparities in the course of HIV infection from the time of infection onwards.
You can find more information about the collaboration on https://www.ctu.mrc.ac.uk/studies/all-studies/c/cascade/.
InCHEHC
The InCHECH Collaboration (International Collaboration on Hepatitis C Elimination in HIV Cohorts), led by the Burnet Institute in Australia, pools data from 15 HIV cohorts from 8 countries. It is the largest cohort of PLWH with well characterised data on hepatitis C virus (HCV) co-infection.
The goal of this collaboration is to research if the micro-elimination of HCV can also be achieved in PLWH.
You can find more information about this collaboration on https://www.burnet.edu.au/projects/414_the_international_collaboration_on_hepatitis_c_elimination_in_hiv_cohorts_inchehc
Partners
